Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?

Proteomics

Volumn 8, Issue 23-24, 2008, Pages 5074-5085

  Vasudev, Naveen S ^a   Ferguson, Roisean E ^a   Cairns, David A ^a   Stanley, Anthea J ^a   Selby, Peter J ^a   Banks, Rosamonde E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; EF fractionation; MARS; Proteomics; Serum; Zoom

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ALPHA 2 ANTIPLASMIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGIOTENSINOGEN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; CARBOXYPEPTIDASE B; CERULOPLASMIN; CLUSTERIN; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR I; FETUIN A; FICOLIN; GELSOLIN; HAPTOGLOBIN; HEMOPEXIN; PIGMENT EPITHELIUM DERIVED FACTOR; PREALBUMIN; RETINOL BINDING PROTEIN; SERUM AMYLOID P; TRANSFERRIN; VITAMIN D BINDING PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HUMAN; ISOELECTRIC FOCUSING; KIDNEY CANCER; MALE; MULTIPLE AFFINITY REMOVAL SYSTEM; NEPHRECTOMY; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REPRODUCIBILITY; TECHNOLOGY; TWO DIMENSIONAL ELECTROPHORESIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; ISOELECTRIC FOCUSING; ISOELECTRIC POINT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEPHRECTOMY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 57649218826     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800497     Document Type: Article

References (37)

1. Lam, J. S., Leppert, J. T., Belldegrun, A. S., Figlin, R. A., Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 2005, 23, 202-212.
2. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A. et al., Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 370, 2103-2111.
3. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C. et al., Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
4. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D. et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.
5. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
6. Anderson, N. L., Polanski, M., Pieper, R., Gatlin, T. et al., The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3, 311-326.
7. Hoffman, S. A., Joo, W. A., Echan, L. A., Speicher, D. W., Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007, 849, 43-52.
8. Whiteaker, J. R., Zhang, H., Eng, J. K., Fang, R. et al., Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 2007, 6, 828-836.
9. Chromy, B. A., Gonzales, A. D., Perkins, J., Choi, M. W. et al., Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J. Proteome Res. 2004, 3, 1120-1127.
10. Cho, S. Y., Lee, E. Y., Lee, J. S., Kim, H. Y. et al., Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 2005, 5, 3386-3396.
11. Pieper, R., Gatlin, C. L., Makusky, A. J., Russo, P. S. et al., The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3, 1345-1364.
12. Bjorhall, K., Miliotis, T., Davidsson, P., Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5, 307-317.
13. Echan, L. A., Tang, H. Y., Ali-Khan, N., Lee, K., Speicher, D. W., Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005, 5, 3292-3303.
14. Dekker, L. J., Bosman, J., Burgers, P. C., van Rijswijk, A. et al., Depletion of high-abundance proteins from serum by immunoaffinity chromatography: A MALDI-FT-MS study. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2007, 847, 65-69.
15. Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M. et al., Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 2003, 97, 1663-1671.
16. Banks, R. E., Stanley, A. J., Cairns, D. A., Barrett, J. H. et al., Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ ionization mass spectrometry. Clin. Chem. 2005, 51, 1637-1649.
17. Craven, R. A., Stanley, A. J., Hanrahan, S., Dods, J. et al., Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006, 6, 2853-2864.
18. Zhou, M., Lucas, D. A., Chan, K. C., Issaq, H. J. et al., An investigation into the human serum "interactome". Electrophoresis 2004, 25, 1289-1298.
19. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E. et al., A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074.
20. Brand, J., Haslberger, T., Zolg, W., Pestlin, G., Palme, S., Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 2006, 6, 3236-3242.
21. Okano, T., Kondo, T., Kakisaka, T., Fujii, K. et al., Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6, 3938-3948.
22. Yae, Y., Inaba, S., Sato, H., Okochi, K. et al., Isolation and characterisation of a thermolabile β-2 macroglycoprotein ('thermolabile substance' or 'Hakata antigen') detected by precipitating (auto) antibody in sera of patients with systemic lupus erythematosus. Biochim. Biophys. Acta 1991, 1078, 369-376
23. Doustjalali, S. R., Yusof, R., Yip, C. H., Looi, L. M. et al., Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis 2004, 25, 2392-2401.
24. Huang, H. L., Stasyk, T., Morandell, S., Dieplinger, H. et al., Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27, 1641-1650.
25. Liu, W., Liu, B., Xin, L., Zhang, Y. et al., Down-regulated expression of complement factor I: A potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin. Chim. Acta 2007, 377, 119-126.
26. Dowling, P., O'Driscoll, L., Meleady, P., Henry, M. et al., 2D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007, 28, 4302-4310.
27. Li, X., Gong, Y., Wang, Y., Wu, S. et al., Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 2005, 5, 3423-3441.
28. Jackson, D., Craven, R. A., Hutson, R. C., Graze, I. et al., Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res. 2007, 13, 7370-7379.
29. Ahmed, N., Oliva, K. T., Barker, G., Hoffmann, P. et al., Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005, 5, 4625-4636.
30. Lamb, G. W., McMillan, D. C., Ramsey, S., Aitchison, M., The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 2006, 94, 781-784.
31. Sengupta, S., Lohse, C. M., Cheville, J. C., Leibovich, B. C. et al., The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 2006, 106, 304-312.
32. Magera, J. S., Jr., Leibovich, B. C., Lohse, C. M., Cheville, J. C. et al., Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008, 71, 278-282.
33. Babaian, R. J., Swanson, D. A., Serum haptoglobin: A non-specific tumor marker for renal cell carcinoma. South. Med. J. 1982, 75, 1345-1348.
34. Ozen, H., Uygur, C., Sahin, A., Tekgul, S. et al., Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995, 46, 494-498.
35. Ramsey, S., Lamb, G. W., Aitchison, M., McMillan, D. C., The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br. J. Cancer 2006, 95, 1076-1080.
36. Han, M. J., Herlyn, M., Fisher, A. B., Speicher, D. W., Microscale solution IEF combined with 2D DIGE substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue extracts. Electrophoresis 2008, 29, 695-705.
37. Liu, T., Qian, W. J., Gritsenko, M. A., Xiao, W. et al., High dynamic range characterization of the trauma patient plasma proteome. Mol. Cell. Proteomics 2006, 5, 1899-913.